2022
Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials
Friedman DJ, Du C, Wang Y, Agarwal V, Varosy PD, Masoudi FA, Holmes DR, Reddy VY, Price MJ, Curtis JP, Freeman JV. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC Cardiovascular Interventions 2022, 15: 950-961. PMID: 35512918, PMCID: PMC9370831, DOI: 10.1016/j.jcin.2022.02.029.Peer-Reviewed Original ResearchConceptsRegistry patientsHemorrhagic stroke riskIschemic strokeWarfarin patientsTrial patientsStroke riskLAAO patientsClinical practiceMore pericardial effusionsPeriprocedural ischemic strokePropensity-matched analysisAtrial appendage occlusionCox proportional hazardsPatient-level dataFine-Gray modelMore comorbiditiesPROTECT AFNoncardiovascular deathPericardial effusionHemorrhagic strokeAppendage occlusionDevice implantationTrial criteriaClinical trialsSimilar risk
2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?
Heidenreich PA, Tsai V, Bao H, Curtis J, Goldstein M, Curtis L, Hernandez A, Peterson P, Turakhia MP, Masoudi FA. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Failure 2015, 3: 497-504. PMID: 25982109, DOI: 10.1016/j.jchf.2015.01.012.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionICD implantationOlder patientsTrial criteriaNew York Heart Association functional class IIIAge groupsSocial Security Death IndexPatients age 85Receipt of CRTFunctional class IIICardiac resynchronization therapyVentricular ejection fractionClinical trial criteriaDifferent age groupsPatient ageEjection fractionICD RegistryImproved survivalPrimary outcomeResynchronization therapyTherapy useDeath IndexMean ageClinical trialsRegistry data
2010
Regional Variation in the Use of Implantable Cardioverter-Defibrillators for Primary Prevention
Matlock DD, Peterson PN, Heidenreich PA, Lucas FL, Malenka DJ, Wang Y, Curtis JP, Kutner JS, Fisher ES, Masoudi FA. Regional Variation in the Use of Implantable Cardioverter-Defibrillators for Primary Prevention. Circulation Cardiovascular Quality And Outcomes 2010, 4: 114-121. PMID: 21139094, DOI: 10.1161/circoutcomes.110.958264.Peer-Reviewed Original ResearchConceptsPrimary prevention ICDsProportion of patientsTrial inclusion criteriaInclusion criteriaPrimary preventionTrial criteriaPhysician supplyNational Cardiovascular Data RegistryImplantable cardioverter defibrillatorHospital referral regionsRace-adjusted ratesCross-sectional analysisICD implantationICD placementCardioverter defibrillatorReferral regionsData registryPotential overusePatientsICDDeath variesRate ratioService populationGeographic variationRegional variation
2009
Use of implantable cardioverter defibrillators for primary prevention in the community: Do women and men equally meet trial enrollment criteria?
Daugherty SL, Peterson PN, Wang Y, Curtis JP, Heidenreich PA, Lindenfeld J, Vidaillet HJ, Masoudi FA, behalf of the NCDR O. Use of implantable cardioverter defibrillators for primary prevention in the community: Do women and men equally meet trial enrollment criteria? American Heart Journal 2009, 158: 224-229. PMID: 19619698, DOI: 10.1016/j.ahj.2009.05.018.Peer-Reviewed Original ResearchConceptsTrial enrollment criteriaPrimary prevention ICD implantationEnrollment criteriaICD implantationMADIT-IIMultivariable analysisPrimary preventionTrial criteriaNational Cardiovascular Data Registry ICD RegistryPrimary prevention ICD placementImplantable cardioverter defibrillator implantationSCD-HeFT trialsCardioverter-defibrillator implantationSudden cardiac deathImplantable cardioverter defibrillatorDefibrillator implantationSCD-HeFTYounger patientsCardiac deathICD RegistryICD placementNational cohortCardioverter defibrillatorOlder womenPatients